Rubius Therapeutics Raises $100 Million in Crossover Financing Post author:Sam Post published:February 28, 2018 Post category:BioPharma Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing. Source: BioSpace You Might Also Like NeoTract, Inc.'s Minimally Invasive UroLift System For Enlarged Prostate Now Shown To Be Durable Through Five Years: Results From Pivotal L.I.F.T. Randomized Study Presented March 26, 2017 Teva, Union Reach Deal on HQ Layoffs for Administrative Staff January 4, 2018 Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression November 8, 2017
NeoTract, Inc.'s Minimally Invasive UroLift System For Enlarged Prostate Now Shown To Be Durable Through Five Years: Results From Pivotal L.I.F.T. Randomized Study Presented March 26, 2017
Sage Therapeutics Stock Rockets on Two Positive Phase III Trials in Postpartum Depression November 8, 2017
